Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Phase 2 Study of a Patient-Specific Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer With Minimal Residual Disease Following Surgical Resection and Standard Adjuvant Chemotherapy

Next Previous
X
Search
Trial Profile

A Randomized, Open-Label, Phase 2 Study of a Patient-Specific Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer With Minimal Residual Disease Following Surgical Resection and Standard Adjuvant Chemotherapy

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GRANITE 001 (Primary) ; Atezolizumab; Ipilimumab
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GRANITE-CRC-ADJUVANT
  • Sponsors Gritstone bio

    • Most Recent Events

    • 21 Nov 2022 Status changed from recruiting to discontinued.
    • 10 Mar 2022 According to a Gritstone bio media release, the first patient was enrolled for inclusion in the study.
    • 10 Mar 2022 Status changed from planning to recruiting, according to a Gritstone bio media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top